内容紹介
Summary
Antiemetic therapy with aprepitant, palonosetron, and dexamethasone is recommended for moderately emetogenic chemotherapy in several guidelines to prevent chemotherapy—induced nausea and vomiting. There is a lack of information about the efficacy and safety of antiemetic therapy with aprepitant, palonosetron, and dexamethasone in patients treated with oxaliplatin in Japan. We recruited patients with untreated colorectal cancer who underwent oxaliplatin—based chemotherapy. All patients were treated with aprepitant, palonosetron, and dexamethasone. The complete response and complete protection rates were analyzed. A total of 52 patients were enrolled in this clinical trial. The complete response rate overall, and in the acute and delayed phases was 92.3%, 98.1%, and 92.3%, respectively. The complete protection rate overall and in the acute and delayed phases was 73.1%, 86.5%, and 73.1%, respectively. Grade 3—4 non—hematological toxicity did not occur. Antiemetic therapy with aprepitant, palonosetron, and dexamethasone is effective and safe in patients treated with oxaliplatin.
要旨
制吐薬適正使用ガイドラインにおいて,中等度催吐性レジメンに対するアプレピタント,パロノセトロン,デキサメタゾンを用いた制吐療法(3剤併用制吐療法)が推奨されている。しかし本邦では,オキサリプラチン含有レジメンに対する有効性についてのprospective studyは少ない。我々の研究では大腸癌初回がん化学療法患者52名を登録し,3剤併用制吐療法を適用して有効性と安全性を評価した。主要評価項目はCR率およびCP率とし,全期間,急性期,遅発期におけるCR率はそれぞれ92.3%,98.1%,92.3%,全期間,急性期,遅発期におけるCP率は73.1%,86.5%,73.1%であった。Grade 3およびGrade 4の非血液毒性は確認されなかった。これらの結果から,3剤併用制吐療法はオキサリプラチン含有レジメンに対して有効かつ安全であると考えられた。
目次
Antiemetic therapy with aprepitant, palonosetron, and dexamethasone is recommended for moderately emetogenic chemotherapy in several guidelines to prevent chemotherapy—induced nausea and vomiting. There is a lack of information about the efficacy and safety of antiemetic therapy with aprepitant, palonosetron, and dexamethasone in patients treated with oxaliplatin in Japan. We recruited patients with untreated colorectal cancer who underwent oxaliplatin—based chemotherapy. All patients were treated with aprepitant, palonosetron, and dexamethasone. The complete response and complete protection rates were analyzed. A total of 52 patients were enrolled in this clinical trial. The complete response rate overall, and in the acute and delayed phases was 92.3%, 98.1%, and 92.3%, respectively. The complete protection rate overall and in the acute and delayed phases was 73.1%, 86.5%, and 73.1%, respectively. Grade 3—4 non—hematological toxicity did not occur. Antiemetic therapy with aprepitant, palonosetron, and dexamethasone is effective and safe in patients treated with oxaliplatin.
要旨
制吐薬適正使用ガイドラインにおいて,中等度催吐性レジメンに対するアプレピタント,パロノセトロン,デキサメタゾンを用いた制吐療法(3剤併用制吐療法)が推奨されている。しかし本邦では,オキサリプラチン含有レジメンに対する有効性についてのprospective studyは少ない。我々の研究では大腸癌初回がん化学療法患者52名を登録し,3剤併用制吐療法を適用して有効性と安全性を評価した。主要評価項目はCR率およびCP率とし,全期間,急性期,遅発期におけるCR率はそれぞれ92.3%,98.1%,92.3%,全期間,急性期,遅発期におけるCP率は73.1%,86.5%,73.1%であった。Grade 3およびGrade 4の非血液毒性は確認されなかった。これらの結果から,3剤併用制吐療法はオキサリプラチン含有レジメンに対して有効かつ安全であると考えられた。